Skip to main content
. Author manuscript; available in PMC: 2023 Jan 27.
Published in final edited form as: Cell Rep. 2022 Dec 20;41(12):111859. doi: 10.1016/j.celrep.2022.111859

Figure 3. Frequent discordance of actionable genomic alterations in primary and metastatic urothelial carcinomas.

Figure 3.

(A) Targeted sequencing of 119 paired primary and metastatic urothelial cancer samples. Each column represents an individual patient with the mutational status of the primary tumor on the left and the metastatic specimen on the right. Only oncogenic and likely oncogenic mutations, fusions, and ERBB2 amplifications were included in the OncoPrint.

(B) Comparison of tumor mutational burden (TMB) in primary and metastatic tumor sites.

(C) Mutational concordance of select frequently mutated genes including targetable kinases and chromatin-modifying genes. Percentages reflect only patients with a mutation in the designated gene in either the primary or metastasis or both.

See also Figure S3.